A New Molecule to Prevent Contrast-Induced Kidney Injury

Administrating Recombinant Human C1-Esterase-Inhibitor (rhC1INH) before coronary angiography might mitigate contrast induced kidney injury. In addition, it shows a favorable safety profile in populations with multiple comorbidities. 

Una nueva molécula para evitar la nefropatía por contraste

The contrast material used in all our diagnostic tests and therapeutic procedures causes tubular cytotoxicity and ischemia/reperfusion injury. rhC1INH had been effective at mitigating this mechanism in experimental models and was therefore ready to be tested against placebo in humans. 

This study included 77 patients with chronic kidney failure blindly randomized to 50 UI/kg rhC1INH vs placebo in elective angiography procedures.

Primary end point was peak change of urinary neutrophil gelatinase-associated lipocalin within 48 h, a specific marker of kidney injury. 


Read also: ST-Segment Elevation Myocardial Infarction in the Time of COVID-19.


Median peak change of urinary neutrophil gelatinase-associated lipocalin was 4.7 ng/ml for the active branch vs. 22.5 ng/ml for the placebo branch (p=0.038) in the per-protocol population, but not in the modified intention-to-treat analysis or in patients treated with PCI after the angiography. 

The incidence of contrast induced kidney injury as per the classic definition was comparable between both groups. Adverse events at 3 months were also similar. 

Conclusion

Prior administration of the recombinant Human C1-Esterase-Inhibitor could mitigate contrast induced kidney injury. And even though, for now, this has only been shown for a surrogate marker of kidney injury, the safety feature of this new molecule is now clear.

j-acc-cardiovascular-interv-nefroproteccion-estudio-randomizado

Original Title: A Randomized Trial of Recombinant Human C1-Esterase-Inhibitor in the Prevention of Contrast-Induced Kidney Injury.

Reference: Anneza Panagiotou et al. J Am Coll Cardiol Intv 2020, article in press.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

SMART-CHOICE 3 | Efficacy and Safety of Clopidogrel vs Aspirin Monotherapy in High Risk Patients after Percutaneous Coronary Intervention

Courtesy of Dr. Juan Manuel Pérez. After post percutaneous coronary intervention (PCI) standard duration dual antiplatelet therapy (DAPT), the optimal long term monotherapy strategy is...

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...